# CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

> **NCT04089215** · PHASE2 · UNKNOWN · sponsor: **Shanghai Ming Ju Biotechnology Co., Ltd.** · enrollment: 82 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** CD19-targeted Chimeric Antigen Receptor (CAR) T Cells

## Key facts

- **NCT ID:** NCT04089215
- **Lead sponsor:** Shanghai Ming Ju Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-11
- **Primary completion:** 2021-09-10
- **Final completion:** 2024-09-30
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04089215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04089215, "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04089215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*